Results 171 to 180 of about 36,022 (296)

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet   +2 more
wiley   +1 more source

The last‐step integrator thesis: Heterarchical control of the mammalian gastrointestinal tract

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Heterarchy of control of the gastrointestinal tract. The production mechanisms (i.e. epithelial cells and muscles) are shown at the bottom in green. Above them are some of the many mechanisms that provide control inputs to these production mechanisms.
William Bechtel, Leonardo Bich
wiley   +1 more source

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis

open access: yesRapid Communications in Mass Spectrometry, Volume 40, Issue 23, 15 December 2026.
ABSTRACT Rationale Retatrutide (LY3437943) is a novel long‐acting triple incretin receptor agonist that targets the glucagon‐like peptide‐1 receptor (GLP‐1R), glucose‐dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Its pronounced effects on body composition and metabolic health, combined with increasing off‐label use
Gabriel Reis Alves Carneiro   +6 more
wiley   +1 more source

Global Landscape and Thematic Evolution of Selective GLP‐1 Receptor Agonists and GLP‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang   +6 more
wiley   +1 more source

Conditional overexpression of PPARα in intestinal epithelium diminishes GIP enteroendocrine cells and circulating hormone levels. [PDF]

open access: yesMol Metab
Socha JJ   +8 more
europepmc   +1 more source

Global analysis of thermal and chemical denaturation using CheMelt: Thermodynamic dissection of highly thermostable de novo designed proteins

open access: yesProtein Science, Volume 35, Issue 11, November 2026.
Abstract De novo protein design often produces thermostable proteins that denature above 100°C, which complicates the analysis of their stability. Thermostable proteins can be unfolded by combined chemical and thermal denaturation followed by global analysis of multiple melting curves.
Vili Lampinen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy